Author(s):
Rehan Haider, Asghar Mehdi, Geetha Kumari Das, Zameer Ahmed, Sambreen Zameer
Email(s):
rehan_haider64@yahoo.com , drasgharmehdi@gmail.com , dasgeetha342@gmail.com , ahmed_dr2003@yahoo.com , sambreenzameer@yahoo.com
DOI:
10.52711/2231-5659.2025.00058 
Address:
Rehan Haider, Asghar Mehdi, Geetha Kumari Das, Zameer Ahmed, Sambreen Zameer
1PhD, Riggs Pharmaceutical Department of Pharmacy, University of Karachi.
2Ph.D., Head of Department Pharmacology Fazaia Ruth Pfau Medical College Air College, Karachi.
3Ph.D., GD Pharmaceutical Inc., OPJS University, Rajasthan.
4PhD, Assistant Professor Dow University of Health Sciences, Karachi.
5PhD, Department of Pathology, Dow University of Health Sciences, Karachi.
*Corresponding Author
Published In:
Volume - 15,
Issue - 4,
Year - 2025
ABSTRACT:
Cannabinoids, the living compounds in the grass, have taken substantial consideration on account of their healing potential and relating to sports use. Among the ruling class, tetrahydrocannabinol (THC) and cannabidiol (CBD) are known for their belongings on the principal central nervous system. The endocannabinoid structure (ECS) plays an important role in modulating reward, ambition, and stress answers, making it main to hang-up research. Evidence suggests that never-ending marijuana use grant permission influences marijuana use disorder (CUD), characterized by removal syndromes, resistance, and resumed use despite adverse belongings. While THC is popular for allure habit-forming potential, CBD exhibits anxiolytic and likely anti-habit-forming possessions. Moreover, cannabinoids influence the dependence process of added essences like opioids and stimulants by either exacerbating reliance or contributing healing benefits for retraction and relapse stop. Advances in understanding the neurobiology of cannabinoid addiction focal point the need for nuanced requirements, healing use, and community health methods. Future research should aim to bridge existing information breaks and determine the long-term impact of cannabinoids in alcohol abuse circumstances.
Cite this article:
Rehan Haider, Asghar Mehdi, Geetha Kumari Das, Zameer Ahmed, Sambreen Zameer. Cannabinoids and Addiction. Asian Journal of Research in Pharmaceutical Sciences. 2025; 15(4):395-8. doi: 10.52711/2231-5659.2025.00058
Cite(Electronic):
Rehan Haider, Asghar Mehdi, Geetha Kumari Das, Zameer Ahmed, Sambreen Zameer. Cannabinoids and Addiction. Asian Journal of Research in Pharmaceutical Sciences. 2025; 15(4):395-8. doi: 10.52711/2231-5659.2025.00058 Available on: https://ajpsonline.com/AbstractView.aspx?PID=2025-15-4-8
REFERENCES:
1. Volkow ND, Baler RD, Compton WM, Weiss SRB. Adverse energy belongings of pot use. N Engl J Med. 2014; 370(23): 2219–27.
2. Hall W, Degenhardt L. The antagonistic strength belongings of incessant marijuana use. Drug Test Anal. 2014; 6(1–2): 39–45.
3. Lu HC, Mackie K. An influx to the inside cannabinoid arrangement. Biol Psychiatry. 2016;79(7):516–25.
4. Gardner EL. A new view of marijuana resistance and dependence. Drug Alcohol Depend. 2002;67(2):91–6.
5. Budney AJ, Hughes JR. The marijuana retraction condition. Curr Opin Psychiatry. 2006;19(3):233–8.
6. Morgan CJA, Das RK, Joye A, Curran HV, Kamboj SK. Cannabidiol reduces smoke devouring in crop smokers: preliminary judgments. Addict Behav. 2013; 38(9): 2433–6.
7. Wiese B, Wilson-Poe AR. Emerging evidence for marijuana’ duty in opioid use disorder. Cannabis Cannabinoid Res. 2018; 3(1): 179–89.
8. Andre CM, Hausman JF, Guerriero G. Cannabis sativa: The plant of the thousand and individual fragments. Front Plant Sci. 2016; 7:19.
9. ElSohly MA, Slade D. Chemical elements of pot: the complex combination of organic cannabinoids. Life Sci. 2005; 78(5): 539–48.
10. Huestis MA. Human cannabinoid pharmacokinetics. Chem Biodivers. 2007;4(8):1770–804.
11. Koob GF, Volkow ND. Neurocircuitry of hang-up. Neuropsychopharmacology. 2010;35(1):217–38.
12. Nestler EJ. Is skill an ordinary microscopic road for enslavement? Nat Neurosci. 2005;8(11):1445–9.
13. Wise RA, Koob GF. The happening and sustenance of drug inclination. Neuropsychopharmacology. 2014;39(2):254–62.
14. veritt BJ, Robbins TW. Neural methods of support for drug addiction: from conduct to tendencies to drive. Nat Neurosci. 2005;8(11):1481–9.
15. Sinha R. Chronic stress, dependence on illegal substances, and exposure to inclination. Ann N Y Acad Sci. 2008; 1141:105–30.
16. Kalivas PW, O’Brien C. Drug inclination as a study of plants of produced neuroplasticity. Neuropsychopharmacology. 2008;33(1):166–80.
17. Shaham Y, Shalev U, Lu L, De Wit H, Stewart J. The restoration model of drug relapse: past, methods and important judgments. Psychopharmacology (Berl). 2003; 168(1–2): 3–20.
18. Lu L, Shepard JD, Hall FS, Shaham Y. Effects of incidental framework and retraction on trained suggestion-inferred drug-pursuing conduct in rats. J Neurosci. 2003; 23(30): 10539–45.
19. Erb S, Salmaso N, Rodaros D, Stewart J. A part of the CRF-holding road from the main nucleus of the amygdala to the bed core of the stria terminalis in stress-persuaded restoration of sugar pursuing. Psychopharmacology (Berl). 2001;158(4):360–5.
20. Koob GF. The belief in the bad outcome of excitement: the craving outlook. Eur J Pharmacol. 2015; 753:73–87.
21. Bossert JM, Poles GC, Wihbey KA, Koya E, Shaham Y. Differential belongings of the barrier of dopamine D1-offspring receptors in core accumbens gist or covering on restoration of dope pursuing in rats. J Neurosci. 2007;27(46):12655–63.
22. Di Chiara G, Imperato A. Drugs persecutes by persons a suggestion of choice increase synaptic dopamine concentrations in the mesolimbic arrangement of freely affecting rats. Proc Natl Acad Sci U S A. 1988;85(14):5274–8.
23. Volkow ND, Wang GJ, Fowler JS, Tomasi D. Addiction circuits in the human intellect. Annu Rev Pharmacol Toxicol. 2012; 52:321–36.
24. Berridge KC, Robinson TE. Liking, inadequate, and the incentive-sensitization belief of inclination. Am Psychol. 2016;71(8):670–9.
25. Boileau I, Assaad JM, Pihl RO, Benkelfat C, Leyton M, Diksic M, and others. Alcohol advances dopamine release in the human core accumbens. Synapse. 2003;49(4):226–31.
26. Le Foll B, Goldberg SR. Cannabinoid CB1 receptor antagonists as hopeful new cures for dependence on illegal substances. J Pharmacol Exp Ther. 2005;312(3):875–83.
27. Cheer JF, Wassum KM, Sombers LA, Heien MLAV, Ariansen JL, Aragona BJ, and others. Phasic dopamine release induced by persecuted entities demands cannabinoid receptor incitement. J Neurosci. 2007;27(4):791–5.
28. Solinas M, Goldberg SR, Piomelli D. The endocannabinoid scheme in intelligence reward processes. Br J Pharmacol. 2008;154(2):369–83.
29. Tanda G, Pontieri FE, Di Chiara G. Cannabinoid and dope incitement of mesolimbic dopamine broadcast by an average mu1 opioid receptor system. Science. 1997;276(5321):2048–50.
30. Braida D, Pozzi M, Parolaro D, Sala M. Intracerebroventricular Δ9-tetrahydrocannabinol induces trained place option in rats. Eur J Pharmacol. 2001;416(1–2):75–9.
31. Panlilio LV, Goldberg SR, Justinova Z. Cannabinoid abuse and a habit of activity: dispassionate and preclinical judgments. Clin Pharmacol Ther. 2015;97(6):616–27.
32. Fattore L, Fadda P, Fratta W. Sex distinctnesses in the self-administration of cannabinoids and different drugs of abuse. Psychoneuroendocrinology. 2009;34(Suppl 1): S227–36.
33. Maldonado R, Valverde O, Berrendero F. Involvement of the endocannabinoid order in drug inclination. Trends Neurosci. 2006;29(4):225–32.
34. Budney AJ, Vandrey RG, Hughes JR, Moore BA, Bahrenburg B. Oral plain bordering a river-9-tetrahydrocannabinol restrain marijuana removal manifestations. Drug Alcohol Depend. 2007;86(1):22–9.
35. Vandrey RG, Budney AJ, Moore BA, Hughes JR. A cross-study contrasting of marijuana and cigarette retraction. Am J Addict. 2005;14(1):54–63.
36. Allsop DJ, Copeland J, Norberg MM, Fu S, Molnar A, Lewis J, and others. Quantifying the dispassionate meaning of marijuana retraction. PLoS One. 2012;7(9): e44864.
37. Meier MH, Caspi A, Ambler A, Harrington H, Houts R, Keefe RS, and others. Persistent marijuana consumers show neuropsychological decline from teens to middle years. Proc Natl Acad Sci U S A. 2012;109(40): E2657–64.
38. Yücel M, Solowij N, Respondek C, Whittle S, Fornito A, Pantelis C, and others. Regional mind anomalies guide long-term burdensome marijuana use. Arch Gen Psychiatry. 2008;65(6):694–701.
39. Moore THM, Zammit S, Lingford-Hughes A, Barnes TRE, Jones PB, Burke M, and others. Cannabis use and risk of schizophrenic or concerning feelings and intuition insane energy consequences: an orderly review. Lancet. 2007;370(9584):319–28.
40. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (DSM-5®). 5th ed. Arlington, VA: American Psychiatric Publishing; 2013.
41. Rubino T, Parolaro D. Long lasting results of marijuana uncovering in adulthood. Mol Cell Endocrinol. 2008;286(1–2 Suppl 1):S108–13.
42. Gonzalez-Cuevas G, Martin-Fardon R, Kerr TM, Stouffer DG, Parsons LH, Koob GF, and others. Unique situation potential of cannabidiol for the stop of relapse to dependence on illegal substance: preclinical evidence of law. Neuropsychopharmacology. 2018;43(10):2036–45.
43. Pertwee RG. Targeting the endocannabinoid plan accompanying cannabinoid receptor agonists: pharmacological approaches and healing potential. Philos Trans R Soc Lond B Biol Sci. 2012;367(1607):3353–63.